Core Viewpoint - The Hong Kong stock market has shown significant strength in early 2026, particularly in the AI healthcare sector, with companies like Yidu Tech experiencing notable stock price increases due to positive market expectations and supportive policies [1][2]. Group 1: Company Performance - Yidu Tech achieved a three-day stock price increase from January 2 to January 6, 2026, with a closing price of 5.66 HKD on January 6, reflecting a cumulative rise of over 8% [1]. - The company has been recognized as one of the first partners in the Henan Province National Artificial Intelligence Application Pilot Base (medical field), further solidifying its core advantages in AI healthcare technology [1]. Group 2: Industry Trends - The AI healthcare sector is experiencing strong overall performance driven by favorable policies, including two recent initiatives from Beijing aimed at promoting AI applications in healthcare from 2026 to 2027 [1]. - The "Action Plan" released by Beijing outlines a vision for widespread application of AI technology across the entire healthcare process by 2027, enhancing the quality of medical services for the public [1]. - Institutions are optimistic about the growth potential of the AI healthcare industry, anticipating that the synergy between policy support and clinical demand will accelerate the implementation of AI healthcare technologies [2].

呈交日期: 2026年1月7日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02158 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | 2,500,000,000 | | USD | | 0.00002 USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 2,500,000,000 | USD | | 0.00002 USD | | 50,000 | 本月底法定/註冊股本總額： USD 50,000 第 1 頁 共 10 頁 v 1.1.1 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有 ...

Yidu Tech Inc. 醫渡科技有限公司 (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） (Stock code 股份代號：2158) N O T I F I C AT I O N L E T T E R 通 知 信 函 30 December 2025 Dear Non-registered holders(Note 1) Yidu Tech Inc. (the "Company") – Notice of Publication of 2026 Interim Report (the "Current Corporate Communications") The Current Corporate Communications of the Company have been published in English and Chinese languages and are available on the website of The Stock Exchange of Hong Kong ...

Yidu Tech Inc. 醫渡科技有限公司 (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） (Stock code 股份代號：2158) N O T I F I C AT I O N L E T T E R 通 知 信 函 30 December 2025 Dear Registered Shareholders, Yidu Tech Inc. (the "Company") – Notice of Publication of 2026 Interim Report (the "Current Corporate Communications") The Current Corporate Communications of the Company have been published in English and Chinese languages and are available on the website of The Stock Exchange of Hong Kong Limite ...

（於開曼群島註冊成立的有限公司） (incorporated in the Cayman Islands with limited liability) Stock code 股份代號: 2158 2025/26 中期報告 Interim Report Yidu Te ch In c. 醫渡科技有限公 司 Interim Report 2025/26 中期報告 目錄 | 公司資料 | 2 | | --- | --- | | 財務摘要 | 5 | | 業務回顧 | 6 | | 管理層討論及分析 | 14 | | 企業管治及其他資料 | 19 | | 中期財務資料審閱報告 | 33 | | 中期簡明合併綜合收益表 | 35 | | 中期簡明合併資產負債表 | 37 | | 中期簡明合併權益變動表 | 39 | | 中期簡明合併現金流量表 | 40 | | 中期簡明合併財務資料附註 | 41 | | 釋義 | 77 | 公司資料 執行董事 宮盈盈女士 （董事長） 徐濟銘先生 （首席執行官） 封曉瑛女士 謝麗女士 非執行董事 曾鳴先生 獨立非執行董事 馬維英博士 潘蓉容女士 張林琦教授 審核委員會 潘蓉容女士 （主席 ...

Core Viewpoint - Yidu Technology has been invited to participate in the Henan Provincial Health Industry Development Conference and has signed on as one of the first partners of the National Artificial Intelligence Application Pilot Base (Medical Direction), marking a strategic move in the development of AI in healthcare in China [1][3]. Group 1: Strategic Partnerships and Collaborations - Yidu Technology is positioned as a "core co-builder" of national medical AI innovation, actively participating in the construction of two national AI pilot bases in Beijing and Henan [1][4]. - The collaboration includes partnerships with major tech companies like Baidu and Alibaba, as well as local medical institutions, to create a synergistic ecosystem that integrates technology, data, clinical applications, and AI [3][4]. Group 2: Objectives and Services of the Pilot Base - The National AI Application Pilot Base aims to provide comprehensive pilot services for medical AI products, including algorithm validation, clinical evaluation, and compliance declaration, to accelerate the industrialization of innovative results [3][4]. - Yidu Technology will focus on integrating AI with traditional Chinese medicine, leveraging its expertise in medical data governance and clinical research to support the development of intelligent applications in this field [4][5]. Group 3: Technological Capabilities and Achievements - Yidu Technology has developed the "AI Medical Brain" YiduCore, which has processed nearly 7 billion authorized medical records and collaborates with over 10,000 hospitals, providing a solid foundation for AI model training and optimization [5]. - The company emphasizes its commitment to independent innovation and aims to leverage the pilot base as a strategic support to meet regional development needs while contributing to the "Healthy China 2030" initiative [5].

Core Viewpoint - Yidu Technology has been invited to participate in the Henan Health Industry Development Conference and has signed on as one of the first partners of the National Artificial Intelligence Application Pilot Base (Medical Direction), marking a strategic expansion in the AI healthcare sector [1][3]. Group 1: Strategic Partnerships and Initiatives - The establishment of the National AI Application Pilot Base in Zhengzhou is a key initiative for Henan Province to implement national health strategies and develop the future health industry [3]. - Yidu Technology is collaborating with major tech companies like Baidu and Alibaba, as well as local medical institutions, to create a synergistic ecosystem that integrates technology, data, clinical applications, and AI in healthcare [3][4]. Group 2: Technological Capabilities and Innovations - Yidu Technology's proprietary "AI Medical Brain" YiduCore has processed nearly 7 billion authorized medical records, covering over 10,000 hospital partnerships, providing a solid foundation for AI model training and clinical insights [5]. - The company aims to leverage its experience in AI and data governance to support the integration of AI with traditional Chinese medicine, enhancing the quality of healthcare services in the region [4][5]. Group 3: Future Development and Goals - Yidu Technology plans to continue its focus on independent innovation and align its AI research and implementation with regional development needs, contributing to the "Healthy China 2030" initiative [5].

Group 1 - Company repurchased 93,500 shares at HKD 5.23 per share on December 19, totaling approximately HKD 490,000, with a cumulative repurchase of about 3.44 million shares in December, amounting to over HKD 17.4 million [1] - The repurchase actions reflect the company's confidence in its future development and aim to strengthen market confidence [1] - The founder and chairman of the company, Gong Rujing, was appointed as a member of the advisory committee of the Digital Medicine Research Institute at City University of Hong Kong, indicating recognition from the industry and academia for the company's innovations in AI healthcare [1] Group 2 - The company has made significant strides in international cooperation, being selected as a member of the newly established Health Sustainable Development Working Committee of the Shanghai Cooperation Organization's multi-functional economic and trade platform [1] - The co-founder and CEO, Xu Jiming, was elected as the first council member of the committee, highlighting the company's professional capabilities and authoritative recognition in the international digital health cooperation field [1] - The company's international strategy has expanded its business and client network to six global regions, establishing a mature localized cooperation ecosystem through collaboration with local governments, medical institutions, and research institutes [2]

经济观察网 近日，上海合作组织国家多功能经贸平台（上合家园）卫生可持续发展工作委员会正式成立。国内AI医疗头部企业医渡科技（2158.HK）凭借其 在国际数字健康领域的成功实践与系统化建设能力入选组织成员单位，医渡科技联合创始人、CEO徐济铭当选为委员会第一届理事。此次"成员单位"与"首 届理事"的双重身份认可，是对医渡科技技术实力、行业贡献及管理层专业能力的肯定，也标志着该公司在参与国际多边卫生合作、推动全球健康可持续发 展方面迈出关键一步。 上海合作组织国家多功能经贸平台是在上海合作组织秘书处和重庆市委市政府支持下，由上海合作组织实业家委员会、重庆两江新区管委会等共同搭建的以 经济作为核心的多领域、多功能、非营利性国际合作交流平台。 会上，上海合作组织国家多功能经贸平台总干事、重庆市政协港澳台侨和外事委员会副主任胡开强为委员会授牌，他在发言中指出，加强卫生健康领域合 作，促进卫生健康可持续发展，已成为历届上合组织各成员国元首重要共识。 商务部研究院国际发展合作研究所所长王泺作主题发言。她从政策研究与国际合作的高度，系统阐述了医药产业南向出海的战略意义与现实路径，特别提出 从"单点输血"到"体系赋能"的援外 ...

体验三大升级：让临床试验参与"省心又安心" 本次新上线的CTMS小程序是以试验参与者体验为出发点，实现从"管理导向"向"服务导向"的升级突 破，其深度融入微信生态，在移动端场景下为试验参与者带来了诸多便利： 参与更便捷。试验参与者无需下任何APP，通过微信小程序即可一键查询试验动态：访视时间、地点、 检查项目提前知晓，补贴报销进度实时可查，还能接收智能提醒，此外，小程序已无缝对接北肿的 DTP(药物直达)系统， 让试验参与者能够通过同一入口便捷获取试验相关药品服务，大幅降低了参与门 槛，提供了更贴心的服务体验。 沟通更安全。关键沟通均通过企业微信官方渠道进行，检查报告、试验方案等关键医疗资料通过CTMS 平台加密传输，数据安全可控，规避非官方渠道流转风险。 体验更连贯。借助企业微信自带功能，当CRC人员发生变动时，既往沟通记录、项目信息将实现无缝交 接，避免试验参与者重复沟通、信息对接不畅等问题，让试验过程始终连贯顺畅，减少试验参与者参与 负担和沟通成本。 如何让复杂的临床试验对参与者更"友好"，对管理者更"高效"？动动手指，临床试验的访视安排、报销 进度、用药服务即可一键掌握——这已不再是设想。近日，医渡科 ...